Cardiff Oncology CMO Exits as Interim Replacement Takes Over Ahead of Phase 3
CRDF sits 19% above its 52-week low of $0.757 on light trading volume (0.2× avg).
Summary
Cardiff Oncology's Chief Medical Officer Roger Sidhu left on October 22, 2026, and Leila Alland was signed the next day as interim CMO at $35,000 a month through April 2027. The filing also confirms the authorized common stock increase to 300 million shares approved at the October 22 special meeting.
Key Events · Executive and Board Changes · CRDF
-
Chief Medical Officer Departs
Dr. Roger Sidhu separated from Cardiff Oncology on October 22, 2026 in a mutually agreed transition, leaving the top clinical post open as the company prepares its registrational Phase 3.
-
Interim CMO Hired Part-Time
Leila Alland was engaged October 23, 2026 as interim CMO at a monthly fee of $35,000 for up to 50% of her professional time, under an agreement running to April 22, 2027 unless extended.
-
Authorized Shares Raised to 300M
A Certificate of Amendment effective October 22, 2026 sets total authorized capital at 320,000,000 shares — 300,000,000 common and 20,000,000 preferred — up from the prior 150 million common authorization.
-
Phase 3 Start Targeted for Q1 2027
The press release says Cardiff is preparing to initiate its registrational Phase 3 study in the first quarter of 2027, with median PFS not yet reached in the 30 mg onvansertib arm and all remaining patients on treatment more than 18 months.
Analysis · CRDF · Life Sciences
Cardiff loses its Chief Medical Officer at the worst possible moment — just as it prepares to start a registrational Phase 3 trial in first-line RAS-mutated metastatic colorectal cancer in the first quarter of 2027. The company moved fast, signing Leila Alland as interim CMO the next day at $35,000 a month for up to half her time through April 2027, and she has a credible oncology development resume. Still, an interim, part-time medical chief is a thinner bench than a full-time CMO for a company whose entire value rests on executing that trial. The filing also confirms the previously approved increase in authorized common stock to 300 million shares (320 million total including 20 million preferred), which gives Cardiff room to raise the cash it needs — the Q2 10-Q carried a going concern warning — but that headroom is also future dilution for existing holders.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.7% of the 1698 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDF was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.9M. The 52-week trading range was $0.76 to $3.31. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.